<!--
source: https://www.ncbi.nlm.nih.gov/books/NBK513253/
-->
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width">
<link rel="shortcut icon" href="https://ontomatica.io/static/image/logo/onto-symbol-w252-h252.svg"/>
<title>
Diabetes Mellitus Type 2
</title>
<meta name="DC.Date" content="2020/11/20">
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK513253/">
<meta name="description" content="Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia. It may be due to impaired insulin secretion, resistance to peripheral actions of insulin, or both. According to the International Diabetes Federation (IDF), approximately 415 million adults between the ages of 20 to 79 years had diabetes mellitus in 2015.[1]&nbsp;DM is proving to be a global public health burden as this number is expected to rise to another 200 million by 2040.[1]&nbsp;Chronic hyperglycemia in synergy with the other metabolic aberrations in&nbsp;patients with diabetes mellitus can cause damage to various organ systems, leading to the development of disabling and life-threatening health complications, most prominent of which are microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular complications leading to a 2-fold to a&nbsp;4-fold increased risk of cardiovascular diseases. In this review, we provide an overview of the pathogenesis, diagnosis, clinical presentation, and principles of management of diabetes.">
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK513253/">
<link rel="stylesheet" href="figpopup.css" type="text/css" media="screen">
<link rel="stylesheet" href="books.css" type="text/css">
<link rel="stylesheet" href="books_print.css" type="text/css" media="print">
<style type="text/css">
p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}
</style>
<link rel="shortcut icon" href="https://www.ncbi.nlm.nih.gov/favicon.ico">
<link type="text/css" rel="stylesheet" href="3395586.css">
<link type="text/css" rel="stylesheet" href="3882866.css" media="print">
<style>
.ncbi-alerts .ncbi-alert__shutdown-outer { position: relative; background-color: #f4e3db; border-left: 8px solid #d54309;  background-image: url("data:image/svg+xml,%3C%3Fxml version='1.0' encoding='UTF-8'%3F%3E%3Csvg xmlns='http://www.w3.org/2000/svg' width='126' height='126' viewBox='0 0 126 126'%3E%3Cpath fill='%231B1B1B' d='M117.18,31.592 C111.585,22.006 103.995,14.416 94.409,8.821 C84.821,3.226 74.354,0.429 63.001,0.429 C51.649,0.429 41.18,3.226 31.593,8.821 C22.006,14.415 14.416,22.005 8.821,31.592 C3.225,41.179 0.428,51.649 0.428,63 C0.428,74.351 3.226,84.82 8.82,94.408 C14.415,103.992 22.005,111.584 31.592,117.179 C41.179,122.774 51.648,125.571 63,125.571 C74.352,125.571 84.822,122.774 94.408,117.179 C103.994,111.585 111.584,103.994 117.179,94.408 C122.773,84.82 125.57,74.35 125.57,63 C125.57,51.649 122.773,41.178 117.18,31.592 Z M73.43,102.025 C73.43,102.786 73.184,103.423 72.696,103.939 C72.208,104.455 71.61,104.712 70.903,104.712 L55.26,104.712 C54.554,104.712 53.929,104.441 53.386,103.898 C52.843,103.355 52.572,102.73 52.572,102.025 L52.572,86.546 C52.572,85.84 52.843,85.215 53.386,84.672 C53.929,84.129 54.554,83.858 55.26,83.858 L70.903,83.858 C71.61,83.858 72.209,84.116 72.696,84.631 C73.184,85.149 73.43,85.785 73.43,86.546 L73.43,102.025 Z M73.266,73.999 C73.211,74.542 72.927,75.018 72.412,75.425 C71.895,75.832 71.258,76.035 70.498,76.035 L55.425,76.035 C54.664,76.035 54.012,75.832 53.469,75.425 C52.926,75.018 52.654,74.542 52.654,73.999 L51.269,23.404 C51.269,22.751 51.54,22.263 52.083,21.937 C52.627,21.503 53.279,21.285 54.039,21.285 L71.965,21.285 C72.726,21.285 73.377,21.502 73.92,21.937 C74.463,22.263 74.733,22.752 74.733,23.404 L73.266,73.999 Z'/%3E%3C/svg%3E%0A");}.ncbi-alerts .ncbi-alert__info-outer { position: relative; background-color: #e7f6f8; border-left: 8px solid #00bde3; background-image: url("data:image/svg+xml,%3C%3Fxml version='1.0' encoding='UTF-8'%3F%3E%3Csvg xmlns='http://www.w3.org/2000/svg' width='126' height='126' viewBox='0 0 126 126'%3E%3Cpath fill='%231B1B1B' d='M117.18,31.592 C111.585,22.006 103.995,14.416 94.409,8.821 C84.821,3.226 74.354,0.429 63.001,0.429 C51.649,0.429 41.179,3.226 31.593,8.821 C22.006,14.415 14.416,22.005 8.821,31.592 C3.225,41.179 0.428,51.649 0.428,63 C0.428,74.352 3.226,84.82 8.82,94.408 C14.415,103.993 22.005,111.584 31.592,117.179 C41.179,122.774 51.648,125.571 63,125.571 C74.352,125.571 84.822,122.774 94.408,117.179 C103.994,111.585 111.584,103.994 117.179,94.408 C122.773,84.821 125.57,74.351 125.57,63 C125.57,51.648 122.773,41.178 117.18,31.592 Z M52.572,16.071 C52.572,15.31 52.816,14.686 53.305,14.197 C53.794,13.709 54.419,13.464 55.179,13.464 L70.823,13.464 C71.583,13.464 72.208,13.709 72.695,14.197 C73.183,14.686 73.429,15.31 73.429,16.071 L73.429,29.107 C73.429,29.867 73.183,30.492 72.695,30.98 C72.208,31.469 71.583,31.713 70.823,31.713 L55.179,31.713 C54.419,31.713 53.794,31.469 53.305,30.98 C52.816,30.492 52.572,29.867 52.572,29.107 L52.572,16.071 Z M83.857,102.107 C83.857,102.867 83.611,103.492 83.124,103.979 C82.637,104.468 82.012,104.712 81.25,104.712 L44.75,104.712 C43.989,104.712 43.365,104.468 42.876,103.979 C42.387,103.491 42.143,102.866 42.143,102.106 L42.143,89.07 C42.143,88.308 42.387,87.685 42.876,87.196 C43.365,86.708 43.99,86.463 44.75,86.463 L52.572,86.463 L52.572,60.392 L44.75,60.392 C43.989,60.392 43.365,60.148 42.876,59.659 C42.387,59.171 42.143,58.546 42.143,57.785 L42.143,44.75 C42.143,43.989 42.387,43.365 42.876,42.876 C43.365,42.387 43.99,42.143 44.75,42.143 L70.823,42.143 C71.583,42.143 72.208,42.387 72.695,42.876 C73.183,43.365 73.429,43.989 73.429,44.75 L73.429,86.464 L81.249,86.464 C82.01,86.464 82.635,86.709 83.123,87.197 C83.61,87.685 83.856,88.31 83.856,89.071 L83.856,102.107 L83.857,102.107 Z'/%3E%3C/svg%3E");}.ncbi-alerts div[class$="-outer"]{background-position: 28px 20px;  background-size: 32px 32px;  background-repeat: no-repeat;padding:20px 20px 20px 28px;}.ncbi-alerts div[class$="-inner"]{padding-left: 52px; padding-right: 52px;}@media (max-width: 639px){.ncbi-alerts div[class$="-inner"]{padding-left: 0px; padding-right: 0px; padding-top: 52px;}}.ncbi-alerts button.close{cursor: pointer;position:absolute; top: 16px; right: 20px; width: 32px; height: 32px; border:0; background-color: transparent; background-image: url("data:image/svg+xml,%3Csvg version='1.2' xmlns='http://www.w3.org/2000/svg' xmlns:xlink='http://www.w3.org/1999/xlink' overflow='visible' preserveAspectRatio='none' viewBox='0 0 24 24' width='32' height='32'%3E%3Cg%3E%3Cpath xmlns:default='http://www.w3.org/2000/svg' id='window-close' d='M14.9,16.42c-0.13,0.13-0.33,0.14-0.47,0.01c0,0-0.01-0.01-0.01-0.01L12,14l-2.43,2.42 c-0.13,0.13-0.33,0.14-0.47,0.01c0,0-0.01-0.01-0.01-0.01L7.58,14.9c-0.13-0.13-0.14-0.33-0.01-0.47c0,0,0.01-0.01,0.01-0.01L10,12 L7.58,9.57C7.45,9.45,7.44,9.24,7.57,9.1c0,0,0.01-0.01,0.01-0.01L9.1,7.58c0.13-0.13,0.33-0.14,0.47-0.01c0,0,0.01,0.01,0.01,0.01 L12,10l2.43-2.43c0.13-0.13,0.33-0.14,0.47-0.01c0,0,0.01,0.01,0.01,0.01l1.51,1.53c0.13,0.13,0.14,0.33,0.01,0.47 c0,0-0.01,0.01-0.01,0.01L14,12l2.43,2.43c0.13,0.13,0.14,0.33,0.01,0.47c0,0-0.01,0.01-0.01,0.01L14.9,16.42L14.9,16.42z M20.84,4.49C20.53,4.17,20.1,3.99,19.66,4H4.34C3.42,4,2.67,4.75,2.67,5.67l0,0v12.66c0,0.92,0.75,1.67,1.67,1.67l0,0h15.32 c0.92,0,1.67-0.75,1.67-1.67l0,0V5.67C21.34,5.23,21.16,4.8,20.84,4.49z' style='fill: rgb(33, 33, 33);' vector-effect='non-scaling-stroke'/%3E%3C/g%3E%3C/svg%3E");background-size: 32px 32px; background-repeat:no-repeat}.ncbi-alerts button.close:focus{ outline: 1px dotted #000000;}.ncbi-alerts p{margin-bottom: 0px; margin-top: 0px; font-size: 18px; line-height: 28px;}
</style>
</head>
<body class="book-part" id="ui-ncbiexternallink-19">
<div class="grid">
<div class="col twelve_col nomargin shadow">
<div class="wrap">
<div class="page">
<div class="top">
<div class="universal_header" id="universal_header">
<ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar">
<li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="https://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="28977.gif" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li>
</ul>
</div>
<div class="header" style="margin-bottom: 0px;">
</div>
</div>
<div class="content">
<div class="col1">
</div>
<div class="container">
<div id="maincontent" class="content twelve_col col">
<div class="document">
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork">
<div class="meta-content fm-sec"><h1 id="_NBK513253_"><span class="title" itemprop="name">Diabetes Mellitus Type 2</span></h1><p class="contrib-group"><span itemprop="author">Rajeev Goyal</span>; <span itemprop="author">Ishwarlal Jialal</span>.</p><a data-jig="ncbitoggler" href="#__NBK513253_ai__" style="border:0;text-decoration:none" id="ui-ncbitoggler-15" class="ui-widget ui-ncbitoggler" role="button" aria-expanded="false"><span class="ui-ncbitoggler-master-text">Author Information</span><span class="ui-icon ui-icon-triangle-1-e"></span></a><div class="ui-helper-reset" aria-live="assertive"><div style="display:none" class="ui-widget ui-ncbitoggler ui-ncbitoggler-slave" id="__NBK513253_ai__" aria-hidden="true"><p class="contrib-group"></p><h4>Authors</h4><span itemprop="author">Rajeev Goyal</span><sup>1</sup>; <span itemprop="author">Ishwarlal Jialal</span><sup>2</sup>.<p></p><h4>Affiliations</h4><div class="affiliation"><sup>1</sup> Lady Hardinge Medical College, New Delhi, India</div><div class="affiliation"><sup>2</sup> VA MEDICAL CENTER, MATHER , CA</div></div></div><p class="small">Last Update: <span itemprop="dateModified">November 20, 2020</span>.</p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text" id="ui-ncbiinpagenav-16"><div id="article-36052.s1"><div class="goto jig-ncbiinpagenav-goto-container"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true">Go to:</a></span></div><h2 id="_article-36052_s1_" class="ui-helper-clearfix">Introduction</h2><p>Diabetes
 mellitus (DM) is a chronic metabolic disorder characterized by 
persistent hyperglycemia. It may be due to impaired insulin secretion, 
resistance to peripheral actions of insulin, or both. According to the 
International Diabetes Federation (IDF), approximately 415 million 
adults between the ages of 20 to 79 years had diabetes mellitus in 2015.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r1" role="button" aria-expanded="false" aria-haspopup="true">[1]</a>&nbsp;DM is proving to be a global public health burden as this number is expected to rise to another 200 million by 2040.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r1" role="button" aria-expanded="false" aria-haspopup="true">[1]</a>&nbsp;Chronic
 hyperglycemia in synergy with the other metabolic aberrations 
in&nbsp;patients with diabetes mellitus can cause damage to various 
organ systems, leading to the development of disabling and 
life-threatening health complications, most prominent of which are 
microvascular (retinopathy, nephropathy, and neuropathy) and 
macrovascular complications leading to a 2-fold to a&nbsp;4-fold 
increased risk of cardiovascular diseases. In this review, we provide an
 overview of the pathogenesis, diagnosis, clinical presentation, and 
principles of management of diabetes.</p></div><div id="article-36052.s2"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s2_" class="ui-helper-clearfix">Etiology</h2><p>DM
 is broadly classified into three types by etiology and clinical 
presentation, type 1 diabetes, type 2 diabetes, and gestational diabetes
 (GDM). Some other less common types of diabetes include monogenic 
diabetes and secondary diabetes.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r2" role="button" aria-expanded="false" aria-haspopup="true">[2]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r3" role="button" aria-expanded="false" aria-haspopup="true">[3]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r4" role="button" aria-expanded="false" aria-haspopup="true">[4]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r5" role="button" aria-expanded="false" aria-haspopup="true">[5]</a></p><p><b>Type 1 Diabetes Mellitus (T1DM)</b></p><p>Type
 1 diabetes mellitus (T1DM)&nbsp;accounts for 5% to 10% of DM and is 
characterized by autoimmune destruction of insulin-producing beta cells 
in the islets of the pancreas. As a result, there is an absolute 
deficiency of insulin. A combination of genetic susceptivity and 
environmental factors such as viral infection, toxins, or some dietary 
factors have been implicated as triggers for autoimmunity. T1DM is most 
commonly seen in children and adolescents though it can develop at any 
age.</p><p><b>Type 2 Diabetes Mellitus</b></p><p>Type 2 diabetes 
mellitus (T2DM) accounts for around 90% of all cases of diabetes. In 
T2DM, the response to insulin is diminished, and this is defined as 
insulin resistance. During this state, insulin is ineffective and is 
initially countered by an increase in insulin production to maintain 
glucose homeostasis, but over time, insulin production decreases, 
resulting in T2DM. T2DM is most commonly seen in persons older than 45 
years. Still, it is increasingly seen in children, adolescents, and 
younger adults due to rising levels of obesity, physical inactivity, and
 energy-dense diets.</p><p><b>Gestational Diabetes Mellitus</b></p><p>Hyperglycaemia,
 which is first detected during pregnancy, is classified as gestational 
diabetes mellitus (GDM), also known as hyperglycemia in pregnancy. 
Although it can occur anytime during pregnancy, GDM generally affects 
pregnant women during the second and third trimesters. According to the 
American Diabetes Association (ADA), GDM complicates 7% of all 
pregnancies. Women with GDM and their offspring have an increased risk 
of developing type 2 diabetes mellitus in the future.</p><p>GDM can be 
complicated by hypertension, preeclampsia, and hydramnios and may also 
lead to increased operative interventions. The fetus can have increased 
weight and size (macrosomia) or congenital anomalies. Even after birth, 
such infants may have respiratory distress syndrome, and subsequent 
childhood and adolescent obesity. Older age, obesity, excessive 
gestational weight gain, history of congenital anomalies in previous 
children, or stillbirth, or a family history of diabetes are risk 
factors for GDM.</p><p><b>Monogenic Diabetes</b></p><p>A single genetic 
mutation&nbsp;in an autosomal dominant gene&nbsp;causes this type of 
diabetes. Examples of monogenic diabetes include conditions like 
neonatal diabetes mellitus and maturity-onset diabetes of the young 
(MODY). Around 1% to 5% of all diabetes cases are due to monogenic 
diabetes. MODY is a familial disorder and usually presents under the age
 of 25 years.</p><p><b>Secondary Diabetes</b></p><p>Secondary 
diabetes&nbsp;is caused due to the complication of other diseases 
affecting pancreas (for example, pancreatitis), hormone disturbances 
(for example, Cushingâ€™s disease), or due to drugs (for example, 
corticosteroids).</p></div><div id="article-36052.s3"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s3_" class="ui-helper-clearfix">Epidemiology</h2><p>Diabetes
 is a worldwide epidemic. With changing lifestyles and increasing 
obesity, the&nbsp;prevalence of DM has increased worldwide. The global 
prevalence of DM was 425 million in 2017. According to the International
 Diabetes Federation (IDF), in 2015, about 10% of the American 
population had diabetes. Of these, 7 million were undiagnosed. With an 
increase in age, the prevalence of DM also increases. About 25% of the 
population above 65 years of age has diabetes.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r5" role="button" aria-expanded="false" aria-haspopup="true">[5]</a></p></div><div id="article-36052.s4"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s4_" class="ui-helper-clearfix">Pathophysiology</h2><p>In&nbsp;T1DM,
 there is cellular-mediated, autoimmune destruction of pancreatic beta 
cells. T1DM has a strong genetic predisposition. The major 
histocompatibility complex (MHC), also known as human leukocyte antigens
 (HLA), is reported to account for approximately 40% to 50% of the 
familial aggregation of T1DM. The significant determinants are 
polymorphisms of class II <i>HLA</i> genes encoding DQ and DR4-DQ8, with DR3-DQ2, found in 90% of T1DM patients.</p><p>Another
 form of T1DM is latent autoimmune diabetes of adults (LADA). It occurs 
in adulthood, often with a slower course of onset.</p><p>The rate of 
destruction is generally rapid in children and faster in adults. 
Autoantibodies against islet cells, insulin, glutamic acid 
decarboxylase-65 (GAD-65), and zinc transporter 8 (Zn T8) may be 
detected in the serum of such patients. These antibodies wane over time 
and do not have sufficient diagnostic accuracy to be used routinely for 
diagnosis, especially after the first year. With the progressive 
destruction of beta cells, there is little or no secretion of insulin. 
These patients are generally not obese. They are more prone to develop 
other autoimmune disorders such as Addison disease, Graves' disease, 
Hashimoto thyroiditis, celiac disease, among others. A subset of T1DM 
not associated with insulin autoimmunity and not associated with the 
above HLA is termed idiopathic T1DM. It is commoner in African and 
Asians and presents with episodic diabetic ketoacidosis (DKA).</p><p>T2DM
 is an insulin-resistance condition with associated beta-cell 
dysfunction. Initially, there is a compensatory increase in insulin 
secretion, which maintains glucose levels in the normal range. As the 
disease progresses, beta cells change, and the insulin secretion is 
unable to maintain glucose homeostasis, producing hyperglycemia. Most of
 the patients with T2DM are obese or have a higher body fat percentage, 
distributed predominantly in the abdominal region. This adipose tissue 
itself promotes insulin resistance&nbsp;through various inflammatory 
mechanisms, including increased FFA release and adipokine dysregulation.
 Lack of physical activity, prior GDM in those with hypertension, or 
dyslipidemia also increases the risk of developing T2DM. Evolving data 
suggest a role for adipokine dysregulation, inflammation, abnormal 
incretin biology with decreased incretins such as glucagon-like 
peptide-1 (GLP-I) or incretin resistance, hyperglucagonemia, increased 
renal glucose reabsorption and abnormalities in gut microbiota.</p></div><div id="article-36052.s5"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s5_" class="ui-helper-clearfix">History and Physical</h2><p>Patients
 with diabetes mellitus&nbsp;most commonly present with increased 
thirst, increased urination, lack of energy and fatigue, bacterial and 
fungal infections, and delayed wound healing. Some patients can also 
complain of numbness or tingling in hands or feet or with blurred 
vision.</p><p>These patients can have modest hyperglycemia, which can 
proceed to severe hyperglycemia or ketoacidosis due to infection or 
stress. T1DM patients can often present with 
ketoacidosis&nbsp;(DKA)&nbsp;coma as the first manifestation in about 
30% of patients.</p><p>Height, weight, and body mass index (BMI) 
of&nbsp;patients with diabetes mellitus&nbsp;should be recorded. 
Retinopathy needs to be excluded in such patients by an ophthalmologist.
 All pulses should be palpated to examine for peripheral arterial 
disease. Neuropathy should be ruled out by physical examination and 
history and nephropathy by early morning urine albumin/creatinine ratios
 of less than 30 mg/g creatinine.</p></div><div id="article-36052.s6"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s6_" class="ui-helper-clearfix">Evaluation</h2><p><b>Screening</b></p><p>Persons
 older than 40 years of age should be screened annually. More frequent 
screening is recommended for individuals with additional risk factors 
for diabetes.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r6" role="button" aria-expanded="false" aria-haspopup="true">[6]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r7" role="button" aria-expanded="false" aria-haspopup="true">[7]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r8" role="button" aria-expanded="false" aria-haspopup="true">[8]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r9" role="button" aria-expanded="false" aria-haspopup="true">[9]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r10" role="button" aria-expanded="false" aria-haspopup="true">[10]</a></p><ul><li class="half_rhythm"><div>Certain races/ethnicities (Native American, African American, Hispanics&nbsp; or Asian American, Pacific Islander),&nbsp;</div></li><li class="half_rhythm"><div>Overweight or obese persons with&nbsp;a BMI greater than or equal to 25 kg/m2 or 23 kg/m2 in Asian Americans,</div></li><li class="half_rhythm"><div>First-degree relative with diabetes mellitus</div></li><li class="half_rhythm"><div>History of cardiovascular disease, hypertension</div></li><li class="half_rhythm"><div>Low HDL-cholesterol or hypertriglyceridemia,&nbsp;</div></li><li class="half_rhythm"><div>Women with polycystic ovarian syndrome</div></li><li class="half_rhythm"><div>Physical inactivity</div></li><li class="half_rhythm"><div>Conditions associated with insulin resistance, for example,&nbsp;<i>Acanthosis nigricans.</i></div></li></ul><p>Women
 diagnosed with gestational diabetes mellitus (GDM) should have lifelong
 testing at least every three years. For all other patients, testing 
should begin at age 45 years, and if results are normal, patients should
 be&nbsp;tested at a minimum of every 3-years.</p><p>The same tests are used to both screen for and diagnose diabetes. These tests also detect individuals with prediabetes.</p><p><b>Diagnosis</b></p><p>Diabetes
 can be diagnosed either by the hemoglobin A1C criteria or plasma 
glucose concentration (fasting or 2-hour plasma glucose).</p><p><b><i>Fasting Plasma Glucose (FPG)</i></b></p><p>A
 blood sample is taken after an 8 hour overnight fast. As per ADA, 
fasting plasma glucose (FPG) level of more than 126 mg/dL (7.0 mm/L) is 
consistent with the diagnosis.</p><p><i><b>Two-Hour Oral Glucose Tolerance Test (OGTT)</b></i></p><p>In
 this test, the plasma glucose level is measured before and 2 hours 
after the ingestion of 75 gm of glucose. DM is diagnosed if the plasma 
glucose (PG) level in the 2-hour sample is more than 200 mg/dL (11.1 
mmol/L). It is also a standard test but is inconvenient and more costly 
than FPG and has major variability issues. Patients need to consume a 
diet with at least 150 g per day of carbohydrate for 3 to 5 days and not
 take any medications that can impact glucose tolerance, such as 
steroids and thiazide diuretics.</p><p><i><b>Glycated Hemoglobin (Hb) A1C</b></i></p><p>This
 test gives an average of blood glucose over the last 2 to 3 months. 
Patients with an Hb A1C greater than 6.5% (48 mmol/mol) are diagnosed as
 having DM. Hb A1C is a convenient, rapid, standardized test and shows 
less variation due to pre-analytical variables. It is not much affected 
by acute illness or stress.</p><p>Hb A1C is costly and has many issues, 
as discussed below, including lower sensitivity. Hb A1C should be 
measured using the National Glycohemoglobin Standardization Program 
(NGSP) certified method standardized to Diabetes Control and 
Complications Trial (DCCT) assay. It is affected by numerous conditions 
such as sickle cell disease, pregnancy, hemodialysis, blood loss or 
transfusion, or erythropoietin therapy. It has not been well validated 
in non-Caucasian populations.</p><p>Anemia due to deficiency of iron or 
vitamin B12 leads to spurious elevation of Hb A1C, limiting its use in 
countries with a high prevalence of anemia. Also, in children and the 
elderly, the relation between Hb A1C and FPG is suboptimal.</p><p>For 
all of the above tests, if the person is asymptomatic, testing should be
 repeated later to make a diagnosis of diabetes mellitus.</p><p>In 
patients with classic symptoms of hyperglycemia (increased thirst, 
increased hunger, increased urination), random plasma glucose more than 
200 mg/dL is also sufficient to diagnose DM.</p><p>FPG, 2-hour PG during
 75-g GTT, and Hb A1C are equally appropriate for the diagnosis of DM. 
There is no concordance between the results of these tests.</p><p><b>Diagnosis of Gestational Diabetes Mellitus</b></p><p>Pregnant
 women not previously known to have diabetes should be tested for GDM at
 24 to 28 weeks of gestation. ADA and American College of Obstetrics and
 Gynecology (ACOG) recommend using either a 1-step or 2-step approach 
for diagnosing GDM.</p><p><b><i>One-Step Strategy</i></b></p><p>75 gm 
OGTT is performed after an overnight fast. Blood samples are collected 
at fasting for 1 hour and 2 hours. GDM is diagnosed if fasting glucose 
meet or exceed 92 mg/dl (5.1 mmol/l), 1-hour serum glucose of 180 mg/dl 
(10.0 mmol/l) or 2-hour serum glucose of 153 mg/dl (8.5 mmol/l).</p><p><b><i>Two-Step Strategy</i></b></p><ul><li class="half_rhythm"><div>Step
 one: Perform a 50-gram glucose challenge test irrespective of the last 
meal. If PG at 1-hour after the load is greater than or equal to 
140mg/dl (7.8 mmol/l), proceed to step 2.</div></li><li class="half_rhythm"><div>Step
 2: 100 g glucose OGTT is performed after overnight fasting. Cut off 
values are fasting PG 95 or 105 mg/dl (5.5/5.8 mmol/l), 1-hour PG of 180
 or 190 mg/dl (10.0/10.6 mmol/l), 2-hour PG of 155 or 165 mg/dl (8.6/9.2
 mmol/l) or 3-hour PG of 140 or 145 mg/dl (7.8/8.0 mmol/l). GDM is 
diagnosed if two or more PG levels equal&nbsp;or exceed these cutoffs.</div></li></ul></div><div id="article-36052.s7"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s7_" class="ui-helper-clearfix">Treatment / Management</h2><p>For both T1DM and T2DM, the cornerstone of therapy is diet and exercise.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r11" role="button" aria-expanded="false" aria-haspopup="true">[11]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r12" role="button" aria-expanded="false" aria-haspopup="true">[12]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r13" role="button" aria-expanded="false" aria-haspopup="true">[13]</a></p><p>A
 diet low in saturated fat, refined carbohydrates, fructose corn syrup, 
and high in fiber and monounsaturated fats needs to be encouraged. 
Aerobic exercise for a duration of 90 to 150 minutes per week is also 
beneficial. The major target in T2DM patients, who are obese, is weight 
loss.</p><p>If adequate glycemia cannot be achieved, metformin is the 
first-line therapy. Following metformin, many other therapies such as 
oral sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors. 
Glucagon-like peptide-1 (GLP-I) receptor agonists, Sodium-glucose 
co-transporter-2 (SGLT2) inhibitors, pioglitazone, especially if the 
patient has fatty liver disease, alpha-glucosidase inhibitors, and 
insulin, are available. Recent studies have shown that the SGLT2 
inhibitor, empagliflozin (EMPA), and the GLP-1 receptor agonist, 
liraglutide, reduce both significant cardiovascular (CV) events and 
mortality. Hence, in patients with CV disease, these drugs should be 
considered next. For patients with T1DM, a regime of basal-bolus insulin
 is the mainstay of therapy. Also, insulin-pump therapy is a reasonable 
choice. Since hypoglycemia portends increased mortality, preference 
should be given to therapies that do not induce hypoglycemia, for 
example, DPP-4 Inhibitors, SGLT-2 inhibitors, GLP-I receptor agonists, 
and pioglitazone with metformin. The other advantages of SGLT-2 
inhibitors and GLP-I receptor agonists are a reduction in body weight, 
blood pressure (BP), and albuminuria.</p><p>To reduce microvascular 
complications in the majority, the goal Hb A1C should be less than 7%. 
Also, the BP goal should be less than 130/85 mmHg with a preference for 
angiotensin-converting enzyme (ACE)/angiotensin receptor blocker (ARB) 
therapy. Fundal exams should be undertaken as proposed by guidelines and
 urine albumin excretion at least twice a year.</p><p>For the lipid 
panel, the goal should be an LDL-C less than 100 mg/dl if 
no&nbsp;atherosclerotic cardiovascular disease (ASCVD) or less than 70 
mg/dl if ASCVD present. The drug of choice is a statin since these drugs
 reduce CV events and CV mortality. Consider adding ezetimibe and PCSK9 
inhibitors for patients with ASCVD who are not at goal.</p><p>Since the 
different complications and therapies have been detailed in other 
Statpearls review articles, we have outlined only the principles of 
therapy.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r14" role="button" aria-expanded="false" aria-haspopup="true">[14]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r15" role="button" aria-expanded="false" aria-haspopup="true">[15]</a></p></div><div id="article-36052.s8"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s8_" class="ui-helper-clearfix">Differential Diagnosis</h2><p>The
 list of differential diagnosis of diabetes mellitus consists of various
 conditions that would exhibit similar signs and symptoms&nbsp;<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r16" role="button" aria-expanded="false" aria-haspopup="true">[16]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r17" role="button" aria-expanded="false" aria-haspopup="true">[17]</a>:</p><ul><li class="half_rhythm"><div>Drug-induced signs and symptoms due to corticosteroids, neuroleptics, pentamidine, etc</div></li><li class="half_rhythm"><div>Genetic aberrations in beta-cell function and insulin action</div></li><li class="half_rhythm"><div>Metabolic syndrome (syndrome X)<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r18" role="button" aria-expanded="false" aria-haspopup="true">[18]</a></div></li><li class="half_rhythm"><div>Infection</div></li><li class="half_rhythm"><div>Endocrinopathies such as acromegaly, Cushing disease, pheochromocytoma, hypothyroidism, etc<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r19" role="button" aria-expanded="false" aria-haspopup="true">[19]</a></div></li><li class="half_rhythm"><div>Complications of iron overload (hemochromatosis)</div></li><li class="half_rhythm"><div>Conditions affecting the exocrine part of the pancreas such as pancreatitis, cystic fibrosis, etc<a href="https://www.ncbi.nlm.nih.gov/pubmed/31688073" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">[20]</a></div></li></ul></div><div id="article-36052.s9"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s9_" class="ui-helper-clearfix">Prognosis</h2><p>DM
 is associated with increased ASCVD, and treating BP, statin use, 
regular exercise, and smoking cessation are of great importance in 
ameliorating risk. The overall excess mortality in those with T2DM is 
around 15% higher but varies widely. The prevalence of 
vision-threatening diabetic retinopathy in the United States is about 
4.4% among adults with diabetes, while it is 1% for end-stage renal 
disease. Today, with pharmacotherapy for hyperglycemia, as well as 
lowering LDL cholesterol and managing BP with ACE/ARB therapy, with 
other&nbsp;antihypertensive medications and aspirin in secondary 
prevention, vascular complications can be managed adequately resulting 
in a reduction in morbidity and mortality.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r20" role="button" aria-expanded="false" aria-haspopup="true">[21]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r21" role="button" aria-expanded="false" aria-haspopup="true">[22]</a></p></div><div id="article-36052.s10"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s10_" class="ui-helper-clearfix">Complications</h2><p>Persistent
 hyperglycemia in uncontrolled diabetes mellitus can cause several 
complications, both acute and chronic. Diabetes mellitus is one of the 
leading causes of cardiovascular disease (CVD), blindness, kidney 
failure, and amputation of lower limbs. Acute complications include 
hypoglycemia, diabetic ketoacidosis, hyperglycemic hyperosmolar state, 
and hyperglycaemic diabetic coma. Chronic microvascular complications 
are nephropathy, neuropathy, and retinopathy, whereas chronic 
macrovascular complications are coronary artery disease (CAD), 
peripheral artery disease (PAD), and cerebrovascular disease. It is 
estimated that every year 1.4% to 4.7% of middle-aged people with 
diabetes have a CVD event.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r22" role="button" aria-expanded="false" aria-haspopup="true">[23]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r23" role="button" aria-expanded="false" aria-haspopup="true">[24]</a></p></div><div id="article-36052.s11"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s11_" class="ui-helper-clearfix">Deterrence and Patient Education</h2><p>Patients
 must be educated about the importance of blood glucose management to 
avoid complications associated with DM. Stress must be given on 
lifestyle management, including diet control and physical exercise. 
Self-monitoring of blood glucose is an important means for patients 
taking responsibility for their diabetes management. Regular estimation 
of glucose, glycated hemoglobin, and lipid levels is necessary.</p><p>Healthcare
 professionals should educate patients about the symptoms of 
hypoglycemia (such as tachycardia, sweating, confusion) and required 
action (ingestion of 15 to 20 gm of carbohydrate).</p><p>Patients should be motivated to stop smoking. Emphasis is required on regular eye check-ups and foot care.</p></div><div id="article-36052.s12"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s12_" class="ui-helper-clearfix">Pearls and Other Issues</h2><ul><li class="half_rhythm"><div>T1DM&nbsp;is characterized by autoimmune destruction of pancreatic beta cells in the majority.</div></li><li class="half_rhythm"><div>T2DM&nbsp;is caused due to duel defects in insulin resistance and insulin secretion.</div></li><li class="half_rhythm"><div>Gestational diabetes is associated with maternal as well as fetal complications.</div></li><li class="half_rhythm"><div>Exercise and a healthy diet are beneficial in both type 1 and type 2 diabetes mellitus.</div></li><li class="half_rhythm"><div>Novel
 therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors are 
safer since they do&nbsp;not cause hypoglycemia, are weight neutral or 
result in weight loss and BP and impact vascular complications 
favorably.</div></li></ul></div><div id="article-36052.s13"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s13_" class="ui-helper-clearfix">Enhancing Healthcare Team Outcomes </h2><p>The
 diagnosis and management of type 2 diabetes mellitus are with an 
interprofessional team. These patients need an appropriate referral to 
the ophthalmologist, nephrologist, cardiologist, and vascular surgeon. 
Also, patients need to be educated about lifestyle changes that can help
 lower blood glucose. All obese patients should be encouraged to lose 
weight, exercise, and eat a healthy diet. The primary care provider and 
diabetic nurse must encourage all diabetics top smoking and abstain from
 drinking alcohol. The complications of diabetes mellitus are limb and 
life-threatening&nbsp;and seriously diminish the quality of life.<a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r24" role="button" aria-expanded="false" aria-haspopup="true">[25]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r25" role="button" aria-expanded="false" aria-haspopup="true">[26]</a><a class="bk_pop" href="#" data-bk-pop-href="#article-36052.r26" role="button" aria-expanded="false" aria-haspopup="true">[27]</a></p></div><div id="article-36052.s14"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s14_" class="ui-helper-clearfix">Continuing Education / Review Questions</h2><ul><li class="half_rhythm"><div><a href="https://www.statpearls.com/articlelibrary/viewarticle/36052/?utm_source=pubmed&amp;utm_campaign=reviews&amp;utm_content=36052" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Access free multiple choice questions on this topic.</a></div></li><li class="half_rhythm"><div><a href="https://www.statpearls.com/physician/cme/activity/36052/?deg=MD&amp;utm_source=pubmed&amp;utm_campaign=CME&amp;utm_content=36052" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Earn continuing education credits (CME/CE) on this topic.</a></div></li><li class="half_rhythm"><div><a href="https://www.statpearls.com/articlelibrary/commentarticle/36052/?utm_source=pubmed&amp;utm_campaign=comments&amp;utm_content=36052" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Comment on this article.</a></div></li></ul></div><div id="article-36052.s15"><div class="goto jig-ncbiinpagenav-goto-container"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true">Go to:</a></div><h2 id="_article-36052_s15_" class="ui-helper-clearfix">References</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="article-36052.r1">Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. <span><span class="ref-journal">Nat Rev Endocrinol. </span>2018 Feb;<span class="ref-vol">14</span>(2):88-98.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/29219149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29219149</span></a>]</div></dd><dt>2.</dt><dd><div class="bk_ref" id="article-36052.r2">Malek R, Hannat S, Nechadi A, Mekideche FZ, Kaabeche M. Diabetes and Ramadan: A multicenter study in Algerian population. <span><span class="ref-journal">Diabetes Res Clin Pract. </span>2019 Apr;<span class="ref-vol">150</span>:322-330.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30779972" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30779972</span></a>]</div></dd><dt>3.</dt><dd><div class="bk_ref" id="article-36052.r3">Choi YJ, Chung YS. Type 2 diabetes mellitus and bone fragility: Special focus on bone imaging. <span><span class="ref-journal">Osteoporos Sarcopenia. </span>2016 Mar;<span class="ref-vol">2</span>(1):20-24.</span> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372751/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6372751</span></a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30775463" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30775463</span></a>]</div></dd><dt>4.</dt><dd><div class="bk_ref" id="article-36052.r4">Picke
 AK, Campbell G, Napoli N, Hofbauer LC, Rauner M. Update on the impact 
of type 2 diabetes mellitus on bone metabolism and material properties. <span><span class="ref-journal">Endocr Connect. </span>2019 Mar 01;<span class="ref-vol">8</span>(3):R55-R70.</span> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391903/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6391903</span></a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30772871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30772871</span></a>]</div></dd><dt>5.</dt><dd><div class="bk_ref" id="article-36052.r5">Carrillo-Larco
 RM, Barengo NC, Albitres-Flores L, Bernabe-Ortiz A. The risk of 
mortality among people with type 2 diabetes in Latin America: A 
systematic review and meta-analysis of population-based cohort studies. <span><span class="ref-journal">Diabetes Metab Res Rev. </span>2019 May;<span class="ref-vol">35</span>(4):e3139.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30761721" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30761721</span></a>]</div></dd><dt>6.</dt><dd><div class="bk_ref" id="article-36052.r6">Hussain S, Chowdhury TA. The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. <span><span class="ref-journal">Drugs. </span>2019 Feb;<span class="ref-vol">79</span>(3):231-242.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30742277" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30742277</span></a>]</div></dd><dt>7.</dt><dd><div class="bk_ref" id="article-36052.r7">Kempegowda
 P, Chandan JS, Abdulrahman S, Chauhan A, Saeed MA. Managing 
hypertension in people of African origin with diabetes: Evaluation of 
adherence to NICE Guidelines. <span><span class="ref-journal">Prim Care Diabetes. </span>2019 Jun;<span class="ref-vol">13</span>(3):266-271.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30704854" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30704854</span></a>]</div></dd><dt>8.</dt><dd><div class="bk_ref" id="article-36052.r8">Martinez LC, Sherling D, Holley A. The Screening and Prevention of Diabetes Mellitus. <span><span class="ref-journal">Prim Care. </span>2019 Mar;<span class="ref-vol">46</span>(1):41-52.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30704659" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30704659</span></a>]</div></dd><dt>9.</dt><dd><div class="bk_ref" id="article-36052.r9">Thewjitcharoen
 Y, Chotwanvirat P, Jantawan A, Siwasaranond N, Saetung S, Nimitphong H,
 Himathongkam T, Reutrakul S. Evaluation of Dietary Intakes and 
Nutritional Knowledge in Thai Patients with Type 2 Diabetes Mellitus. <span><span class="ref-journal">J Diabetes Res. </span>2018;<span class="ref-vol">2018</span>:9152910.</span> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317123/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6317123</span></a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30671482" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30671482</span></a>]</div></dd><dt>10.</dt><dd><div class="bk_ref" id="article-36052.r10">Willis
 M, Asseburg C, Neslusan C. Conducting and interpreting results of 
network meta-analyses in type 2 diabetes mellitus: A review of network 
meta-analyses that include sodium glucose co-transporter 2 inhibitors. <span><span class="ref-journal">Diabetes Res Clin Pract. </span>2019 Feb;<span class="ref-vol">148</span>:222-233.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30641163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30641163</span></a>]</div></dd><dt>11.</dt><dd><div class="bk_ref" id="article-36052.r11">Lai
 LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK.
 Screening for non-alcoholic fatty liver disease in patients with type 2
 diabetes mellitus using transient elastography. <span><span class="ref-journal">J Gastroenterol Hepatol. </span>2019 Aug;<span class="ref-vol">34</span>(8):1396-1403.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30551263" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30551263</span></a>]</div></dd><dt>12.</dt><dd><div class="bk_ref" id="article-36052.r12">Eckstein
 ML, Williams DM, O'Neil LK, Hayes J, Stephens JW, Bracken RM. Physical 
exercise and non-insulin glucose-lowering therapies in the management of
 Type 2 diabetes mellitus: a clinical review. <span><span class="ref-journal">Diabet Med. </span>2019 Mar;<span class="ref-vol">36</span>(3):349-358.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30536728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30536728</span></a>]</div></dd><dt>13.</dt><dd><div class="bk_ref" id="article-36052.r13">Massey
 CN, Feig EH, Duque-Serrano L, Wexler D, Moskowitz JT, Huffman JC. 
Well-being interventions for individuals with diabetes: A systematic 
review. <span><span class="ref-journal">Diabetes Res Clin Pract. </span>2019 Jan;<span class="ref-vol">147</span>:118-133.</span> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370485/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6370485</span></a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30500545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30500545</span></a>]</div></dd><dt>14.</dt><dd><div class="bk_ref" id="article-36052.r14">Shah
 SR, Iqbal SM, Alweis R, Roark S. A closer look at heart failure in 
patients with concurrent diabetes mellitus using glucose lowering drugs.
<span><span class="ref-journal">Expert Rev Clin Pharmacol. </span>2019 Jan;<span class="ref-vol">12</span>(1):45-52.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30488734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30488734</span></a>]</div></dd><dt>15.</dt><dd><div class="bk_ref" id="article-36052.r15">Chinese
 Diabetes Society; National Offic for Primary Diabetes Care. [National 
guidelines for the prevention and control of diabetes in primary 
care(2018)]. <span><span class="ref-journal">Zhonghua Nei Ke Za Zhi. </span>2018 Dec 01;<span class="ref-vol">57</span>(12):885-893.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30486556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30486556</span></a>]</div></dd><dt>16.</dt><dd><div class="bk_ref" id="article-36052.r16">Petersmann
 A, MÃ¼ller-Wieland D, MÃ¼ller UA, Landgraf R, Nauck M, Freckmann G, 
Heinemann L, Schleicher E. Definition, Classification and Diagnosis of 
Diabetes Mellitus. <span><span class="ref-journal">Exp Clin Endocrinol Diabetes. </span>2019 Dec;<span class="ref-vol">127</span>(S 01):S1-S7.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/31860923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31860923</span></a>]</div></dd><dt>17.</dt><dd><div class="bk_ref" id="article-36052.r17">Kerner W, BrÃ¼ckel J., German Diabetes Association.  Definition, classification and diagnosis of diabetes mellitus. <span><span class="ref-journal">Exp Clin Endocrinol Diabetes. </span>2014 Jul;<span class="ref-vol">122</span>(7):384-6.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/25014088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25014088</span></a>]</div></dd><dt>18.</dt><dd><div class="bk_ref" id="article-36052.r18">Cepeda
 Marte JL, Ruiz-Matuk C, Mota M, PÃ©rez S, Recio N, HernÃ¡ndez D, 
FernÃ¡ndez J, Porto J, Ramos A. Quality of life and metabolic control in 
type 2 diabetes mellitus diagnosed individuals. <span><span class="ref-journal">Diabetes Metab Syndr. </span>2019 Sep - Oct;<span class="ref-vol">13</span>(5):2827-2832.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/31425943" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31425943</span></a>]</div></dd><dt>19.</dt><dd><div class="bk_ref" id="article-36052.r19">Steffensen
 C, Dekkers OM, Lyhne J, Pedersen BG, Rasmussen F, Rungby J, Poulsen PL,
 JÃ¸rgensen JOL. Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A 
Prospective Study of 384 Newly Diagnosed Patients. <span><span class="ref-journal">Horm Metab Res. </span>2019 Jan;<span class="ref-vol">51</span>(1):62-68.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30522146" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30522146</span></a>]</div></dd><dt>20.</dt><dd><div class="bk_ref" id="article-36052.r20">Qin
 Z, Zhou K, Li Y, Cheng W, Wang Z, Wang J, Gao F, Yang L, Xu Y, Wu Y, He
 H, Zhou Y. The atherogenic index of plasma plays an important role in 
predicting the prognosis of type 2 diabetic subjects undergoing 
percutaneous coronary intervention: results from an observational cohort
 study in China. <span><span class="ref-journal">Cardiovasc Diabetol. </span>2020 Feb 21;<span class="ref-vol">19</span>(1):23.</span> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035714/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7035714</span></a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/32085772" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32085772</span></a>]</div></dd><dt>21.</dt><dd><div class="bk_ref" id="article-36052.r21">Nowakowska
 M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, Mallen C, 
Van Marwijk H, Peek N, Perera-Salazar R, Reeves D, Rutter MK, Weng SF, 
Qureshi N, Mamas MA, Kontopantelis E. Correction to: The comorbidity 
burden of type 2 diabetes mellitus: patterns, clusters and predictions 
from a large English primary care cohort. <span><span class="ref-journal">BMC Med. </span>2020 Jan 25;<span class="ref-vol">18</span>(1):22.</span> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982380/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6982380</span></a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/31980024" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31980024</span></a>]</div></dd><dt>22.</dt><dd><div class="bk_ref" id="article-36052.r22">Akalu
 Y, Birhan A. Peripheral Arterial Disease and Its Associated Factors 
among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital,
 Northwest Ethiopia. <span><span class="ref-journal">J Diabetes Res. </span>2020;<span class="ref-vol">2020</span>:9419413.</span> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008281/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7008281</span></a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/32090126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32090126</span></a>]</div></dd><dt>23.</dt><dd><div class="bk_ref" id="article-36052.r23">Patoulias
 D, Papadopoulos C, Stavropoulos K, Zografou I, Doumas M, Karagiannis A.
 Prognostic value of arterial stiffness measurements in cardiovascular 
disease, diabetes, and its complications: The potential role of 
sodium-glucose co-transporter-2 inhibitors. <span><span class="ref-journal">J Clin Hypertens (Greenwich). </span>2020 Apr;<span class="ref-vol">22</span>(4):562-571.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/32058679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32058679</span></a>]</div></dd><dt>24.</dt><dd><div class="bk_ref" id="article-36052.r24">Liakopoulos
 V, FranzÃ©n S, Svensson AM, Miftaraj M, Ottosson J, NÃ¤slund I, 
GudbjÃ¶rnsdottir S, Eliasson B. Pros and cons of gastric bypass surgery 
in individuals with obesity and type 2 diabetes: nationwide, matched, 
observational cohort study. <span><span class="ref-journal">BMJ Open. </span>2019 Jan 15;<span class="ref-vol">9</span>(1):e023882.</span> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340417/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6340417</span></a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30782717" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30782717</span></a>]</div></dd><dt>25.</dt><dd><div class="bk_ref" id="article-36052.r25">Su
 YJ, Chen TH, Hsu CY, Chiu WT, Lin YS, Chi CC. Safety of Metformin in 
Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based 
Real-World Cohort Study. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2019 Aug 01;<span class="ref-vol">104</span>(8):3279-3286.</span> [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30779846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30779846</span></a>]</div></dd><dt>26.</dt><dd><div class="bk_ref" id="article-36052.r26">Choi
 SE, Berkowitz SA, Yudkin JS, Naci H, Basu S. Personalizing Second-Line 
Type 2 Diabetes Treatment Selection: Combining Network Meta-analysis, 
Individualized Risk, and Patient Preferences for Unified Decision 
Support. <span><span class="ref-journal">Med Decis Making. </span>2019 Apr;<span class="ref-vol">39</span>(3):239-252.</span> [<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469997/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6469997</span></a>] [<a href="https://www.ncbi.nlm.nih.gov/pubmed/30767632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30767632</span></a>]</div></dd></dl></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-17"><li><a href="#_article-36052_s1_">Introduction</a></li><li><a href="#_article-36052_s2_">Etiology</a></li><li><a href="#_article-36052_s3_">Epidemiology</a></li><li><a href="#_article-36052_s4_">Pathophysiology</a></li><li><a href="#_article-36052_s5_">History and Physical</a></li><li><a href="#_article-36052_s6_">Evaluation</a></li><li><a href="#_article-36052_s7_">Treatment / Management</a></li><li><a href="#_article-36052_s8_">Differential Diagnosis</a></li><li><a href="#_article-36052_s9_">Prognosis</a></li><li><a href="#_article-36052_s10_">Complications</a></li><li><a href="#_article-36052_s11_">Deterrence and Patient Education</a></li><li><a href="#_article-36052_s12_">Pearls and Other Issues</a></li><li><a href="#_article-36052_s13_">Enhancing Healthcare Team Outcomes </a></li><li><a href="#_article-36052_s14_">Continuing Education / Review Questions</a></li><li><a href="#_article-36052_s15_">References</a></li></ul></div></div></div>
<div class="post-content"><div><div class="half_rhythm"><a href="https://www.ncbi.nlm.nih.gov/books/about/copyright/">Copyright</a> Â© 2020, StatPearls Publishing LLC.<p class="small">This book is distributed under the terms of the Creative Commons Attribution 4.0 International License (<a href="http://creativecommons.org/licenses/by/4.0/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://creativecommons.org/licenses/by/4.0/</a>),
 which permits use, duplication, adaptation, distribution, and 
reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, a link is provided to 
the Creative Commons license, and any changes made are indicated.</p></div><div class="small"><span class="label">Bookshelf ID: NBK513253</span><span class="label">PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/30020625" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">30020625</a></span></div></div></div>
</div>
</div>
</div>
</body></html>